（ 於開曼群島註冊成立的有限公司） （股份代號：1358） 海外監管公告 附屬公司業績 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 PW MEDTECH GROUP LIMITED 普 華 和 順 集 團 公 司 普華和順集團公司（「本公司」，連同其附屬公司統稱為「本集團」）的非全資附屬公司四川睿 健醫療科技股份有限公司（ 股份代碼：874652（）「四川睿健醫療」）已於全國中小企業股份轉 讓系統（「全國中小企業股份轉讓系統」）指定披露平台(www.neeq.com.cn)公佈其二零二五財 年未經審核第一季度報告。四川睿健醫療的財務報表乃按照中國企業會計準則編製。 收益表 | | 截至二零二五年 | 截至二零二四年 | | | --- | --- | --- | --- | | | 三月三十一日 | 三月三十一日 | | | | 止三個月 | 止三個月 | 按期變動 | | | ...

PW MEDTECH GROUP LIMITED 普华和顺集团公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：1358） NOTIFICATION LETTER 通知信函 Dear Non-Registered Shareholders(Note 1) , PW Medtech Group Limited (the "Company") – Notice of publication of (i) Annual Report 2024, and (ii) Circular relating to proposed granting of general mandates to repurchase shares and to issue new shares of the Company and proposed re-election of the retiring directors of the Company and notice of the 2025 A ...

PW MEDTECH GROUP LIMITED 普华和顺集团公司 (Incorporated in the Cayman Islands with limited liability) It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the Branch Share Registrar at the above-mentioned address by post or by email to is-ecom@vistra.com. If the C ...

PW MEDTECH GROUP LIMITED 普 華 和 順 集 團 公 司 （ 於開曼群島註冊成立之有限公司） （股份代號：1358） 二零二五年股東週年大會通告 茲通告PW Medtech Group Limited普華和順集團公司（「本公司」）謹訂於二零二五年六月十日 （ 星期二 ）上午十時正假座中國北京市平谷區盤龍西路23 號院1 號樓舉行股東週年大會（「二 零二五年股東週年大會」），以處理以下事項（ 除另有界定外，本通告所用詞彙與本公司日期 為二零二五年四月二十二日之致本公司股東通函（「通函」）所界定者具有相同涵義）： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 1. 考慮、 省覽及 採納本 公司截至 二零二 四年十 二月三 十一日 止年度之 經審核 綜合財 務報 表及董事會與核數師報告； 2. 宣派截至二零二四年十二月三十一日止年度的末期股息每股股份5.3港仙； 「動議： (a) 在下文(b)段的規限下，一般及無條件批准董事於有關 ...

PW MEDTECH GROUP LIMITED 普 華 和 順 集 團 公 司 （ 於開曼群島註冊成立的有限公司） （股份代號：1358） 建議授出購回股份及 此 乃 要 件 請 即 處 理 閣 下 如 對 本 通函 的 任 何 方 面 或 應 採 取的 行 動 有 任 何 疑 問 ， 應 諮詢 閣 下 的股 票 經 紀 或 其 他 註冊證券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已出售或轉讓名下全部PW Medtech Group Limited普華和順集團公司股份，應立即將 本 通 函 連 同隨 附 的 代 表 委 任 表 格送 交 買 主 或 承 讓 人 ，或 經 手 買 賣 或 轉 讓 的銀 行 、 股 票 經 紀 或其他代理商，以便轉交買主或承讓人。 香 港 交 易 及結 算 所 有 限 公 司 及 香港 聯 合 交 易 所 有 限 公司 對 本 通 函 的 內 容 概不 負 責 ， 對 其 準 確 性 或 完 整性 亦 不 發 表 任 何 聲 明， 並 明 確 表 示 ， 概 不對 因 本 通 函 全 部 或 任何 部 分 內 容 而 產 生或因倚賴該等內容而引致的任何損失承擔 ...

Company Overview - The company is a leading player in the Chinese medical device industry, focusing on high-growth and high-margin segments such as infusion devices, blood purification products, and regenerative medical biomaterials [4]. - The company has a strong R&D capability and a comprehensive distribution network, maintaining a leading market position in the infusion device sector, including non-PVC infusion devices and precision filtration infusion devices [6]. - The company is the first in China to obtain registration for high-flow blood dialysis devices, indicating its leadership in the blood purification market [6]. - The product pipeline in regenerative medical biomaterials is extensive, utilizing advanced tissue regeneration material technology for various applications, including hernia repair and aesthetic injections [6]. - The company has been listed on the Hong Kong Stock Exchange since November 8, 2013, providing a platform for rapid business development [6]. Financial Performance - For the fiscal year ending December 31, 2024, revenue is projected to increase by 13.9% to approximately RMB 768.9 million, up from RMB 675.1 million in 2023 [28]. - Gross profit for the same period is expected to rise by 10.1% to around RMB 419.4 million, compared to RMB 380.9 million in 2023 [28]. - Net profit is forecasted to decline by 6.1% to approximately RMB 192.5 million, down from RMB 205.0 million in 2023 [28]. - Profit attributable to the company's owners is anticipated to decrease by 1.6% to about RMB 150.8 million, compared to RMB 153.2 million in 2023 [28]. - Basic and diluted earnings per share for 2024 are projected to be RMB 9.77, slightly down by 0.1% from RMB 9.78 in 2023 [28]. - The proposed final dividend per share for 2024 is 5.3 HK cents, an increase from 4.95 HK cents in 2023, with a total dividend of 9.8 HK cents for 2024 [28]. Market Expansion and Strategy - The company aims to expand its market presence and enhance its product offerings through strategic partnerships and acquisitions [6]. - The company is actively exploring potential mergers and acquisitions to enhance its market position and operational efficiency [38]. - Market expansion plans include entering three new international markets by the end of the year [49]. - The company aims to optimize its sales structure and marketing strategies in response to ongoing industry policy changes [35]. Research and Development - The company is committed to continuous innovation in medical device manufacturing, focusing on high-end infusion devices and intravenous catheter products [6]. - The company emphasizes continuous improvement in R&D capabilities and product innovation to meet the diverse needs of high-quality medical devices [32]. - The company is investing in R&D, allocating 10% of its revenue towards new technology development [48]. - R&D expenses increased by 7.3% from approximately RMB 41.1 million in 2023 to approximately RMB 44.1 million in 2024, primarily due to increased spending in blood purification and regenerative medical biomaterials businesses [76]. Product Development - The company has successfully registered new products, including a pump infusion device and a closed drug preparation and transportation system, expanding its product offerings in the infusion care sector [34]. - The blood purification segment has seen stable sales growth, and the company plans to submit a registration application for a continuous hollow fiber hemodialysis filter in the first half of 2025 [34]. - The company has obtained 58 product registration certificates as of December 31, 2024, covering various medical devices including infusion devices, dialysis equipment, and biological patches [62]. - The company holds a total of 173 product patents, including 67 related to infusion devices, 83 for blood purification products, and 23 for regenerative medical materials, with 57 new patents pending [63]. Corporate Governance - The board believes that consolidating the roles of Chairman and CEO under the same individual strengthens leadership and facilitates business strategy implementation [114]. - The board has maintained compliance with corporate governance standards, ensuring at least three independent non-executive directors, representing one-third of the board [112]. - The company has adopted an independent evaluation mechanism for the board to ensure independent viewpoints and opinions, with a review of its effectiveness until December 31, 2024 [113]. - The board meets at least four times a year to review the company's objectives, strategies, and policies, including significant acquisitions and financial performance [120]. Environmental, Social, and Governance (ESG) Initiatives - The company has established ESG goals related to carbon emissions, pollutant emissions, energy consumption, and water resource management, with annual progress reviews conducted by the board [155]. - The company emphasizes the importance of stakeholder communication and has made adjustments to its ESG strategy based on stakeholder feedback [154]. - The company has reported excellent results in its infusion device, blood purification, and regenerative medical materials businesses, enhancing its competitive edge [162]. - The group has established a quality management system to ensure product safety and compliance with national regulations, particularly for Class III medical devices [171]. Employee and Workplace Policies - The group provides various employee benefits, including a cafeteria, fitness center, and communication subsidies, fostering a harmonious work environment [193]. - The group adheres to national labor laws, ensuring fair employment practices and a safe working environment for all employees [191]. - The group is committed to creating a diverse workplace, employing minority and disabled individuals and providing them with special care [197]. - The group has established a robust occupational health and safety management system to ensure a safe working environment for employees [198].

Core Viewpoint - The company Sichuan Ruijian Medical Technology Co., Ltd. (referred to as "Ruijian Medical") has submitted its initial public offering (IPO) application to the Beijing Stock Exchange, aiming to raise 482 million yuan, with significant connections to Lepu Medical [1][2]. Group 1: Company Overview - Ruijian Medical, established in August 2013, transitioned to a joint-stock system in 2016 and was listed on the New Third Board before being delisted in 2018. It was acquired by Hong Kong-listed company Puhua Heshun in 2021, which now controls 50.55% of Ruijian Medical [2]. - The actual controllers of Ruijian Medical are Pu Zhongjie and his mother-in-law Yufeng Liu, who is the ultimate controlling shareholder of Puhua Heshun [2]. Group 2: Financial Performance - Ruijian Medical's revenue from 2021 to the first nine months of 2024 was 2.61 billion yuan, 3.45 billion yuan, 4.11 billion yuan, and 3.42 billion yuan, respectively. The net profit for the same periods was 679.32 million yuan, 1.04 billion yuan, 1.46 billion yuan, and 926.27 million yuan [5][6]. - The company reported a revenue increase of 17.63% for 2024, reaching 4.83 billion yuan, but net profit and net profit excluding non-recurring items decreased by 12.63% and 5.88%, respectively, marking the first instance of revenue growth without profit growth in three years [5][6]. Group 3: Related Party Transactions - Ruijian Medical engaged in significant related party transactions, selling goods worth a total of 202 million yuan to related parties from 2021 to the first nine months of 2024, with Lepu Medical being a major customer [3][4]. - The company also had arrangements for salary payments with related parties, with amounts paid on behalf of employees totaling 116.96 million yuan, 131.09 million yuan, 148.55 million yuan, and 53 million yuan over the reporting periods [3][4]. Group 4: Market Dynamics - The implementation of volume-based procurement has led to a noticeable decline in the sales prices of Ruijian Medical's main products, with the average selling price of blood dialysis machines and blood perfusion devices dropping by over 10% from 2021 to the first nine months of 2024 [5][7]. - The sales prices for blood dialysis machines were 31.21 yuan, 30.83 yuan, 30.1 yuan, and 27.37 yuan, while blood perfusion devices were priced at 169.41 yuan, 164.14 yuan, 159.81 yuan, and 147.32 yuan during the same periods, reflecting a decline of approximately 12.3% and 13%, respectively [7]. Group 5: Future Plans - Ruijian Medical plans to issue up to 43 million new shares to raise a total of 482 million yuan, which will be allocated to projects related to high-value consumables for blood purification, new blood purification equipment, and the establishment of an innovative research center [7].

| 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | | 股票發行人現金股息公告 | | 發行人名稱 | 普华和顺集团公司 | | 股份代號 | 01358 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度的末期股息 | | 公告日期 | 2025年3月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 末期 | | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.053 HKD | | 股東批准日期 | 2025年6月10日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.053 HKD | | 匯率 | 1 HKD : 1 HKD | | 除淨日 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company's revenue increased by 13.9% to approximately RMB 768.9 million, up from about RMB 675.1 million in 2023[5]. - Gross profit for the same period rose by 10.1% to approximately RMB 419.4 million, compared to about RMB 380.9 million in 2023, resulting in a gross margin of 54.6%[5][7]. - The company's net profit decreased by 6.1% to approximately RMB 192.5 million, down from about RMB 205.0 million in 2023, while the profit attributable to shareholders fell by 1.6% to approximately RMB 150.8 million[5][7]. - Adjusted net profit (non-HKFRS measure) increased by 9.9% to approximately RMB 233.5 million, compared to about RMB 212.4 million in 2023[5]. - The company proposed a final dividend of HKD 0.053 per share, bringing the total dividend for the year to HKD 0.098 per share, slightly down from HKD 0.0985 per share in 2023[5]. - The company reported a net profit of RMB 192,522,000 for the year, after accounting for income tax expenses of RMB 37,231,000[39]. - The company's profit attributable to owners for the year 2024 was RMB 150,780,000, a slight decrease from RMB 153,184,000 in 2023, representing a decline of approximately 0.26%[60]. - The company's total tax expense for 2024 was RMB 37,231,000, compared to RMB 26,044,000 in 2023, reflecting an increase of 42.9%[52]. Business Segments - The infusion device business generated revenue of RMB 286.6 million, a stable increase of 2.0%, accounting for 37.3% of the total revenue during the reporting period[9]. - The blood purification business segment achieved a revenue of RMB 482.3 million, representing a 22.4% increase year-on-year, accounting for 62.7% of the group's total revenue during the reporting period[11]. - For the fiscal year ending December 31, 2024, the total revenue from the infusion business was RMB 286,646,000, while the blood purification business generated RMB 482,257,000, leading to a combined revenue of RMB 768,903,000[39]. - The operating profit for the infusion business was RMB 90,767,000, and for the blood purification business, it was RMB 129,412,000, resulting in a total operating profit of RMB 178,715,000[39]. Research and Development - The company incurred research and development expenses of RMB 44,120,000, compared to RMB 41,130,000 in the previous year, indicating a focus on innovation[23]. - The group has a strong R&D team with 173 patents, including 83 related to blood purification products, and has applied for 57 new patents[15]. - The company incurred research and development expenses for 2024 were RMB 59,703,000, down 21.2% from RMB 75,735,000 in 2023[1]. - Research and development expenses grew by 7.3% from approximately RMB 41.1 million in 2023 to approximately RMB 44.1 million in 2024, attributed to increased R&D spending in blood purification and regenerative medical biomaterials[85]. Market and Industry Trends - The Chinese medical device industry remains resilient, supported by government reforms and policies promoting domestic production and innovation[6][7]. - The group anticipates stable growth in the number of new patients receiving blood purification treatment due to increasing health awareness and improved healthcare policies[10]. - The geographical revenue distribution for 2024 shows China at RMB 643,933 thousand, India at RMB 39,673 thousand, and the Americas at RMB 21,167 thousand, totaling RMB 768,903 thousand[45]. Shareholder and Corporate Governance - The company has initiated a share buyback program with a budget of up to HKD 150 million, aiming to enhance market liquidity and stabilize stock prices[21]. - The board proposed a final dividend of 5.3 HKD cents per share for the year ended December 31, 2024, up from 4.95 HKD cents for the previous year, bringing the total dividend for the year to 9.8 HKD cents per share[123]. - The company has maintained a strong credit risk management policy, with most trade and other receivables coming from state-owned enterprises or major clients with good repayment records[116]. - The company is committed to good corporate governance practices, having adopted the corporate governance code as per the listing rules[125]. Financial Position - The company maintains a healthy cash flow with cash and cash equivalents reaching RMB 1,682.0 million[7]. - The total assets as of December 31, 2024, amounted to RMB 5,160,929,000, slightly up from RMB 5,152,049,000 in 2023[26]. - The total assets of the company as of December 31, 2024, were RMB 4,803,368,000, a slight decrease from RMB 4,824,985,000 in the previous year[27]. - The company's current liabilities increased to RMB 177,440,000 from RMB 149,263,000, reflecting a growth of approximately 18.9% year-over-year[27]. Employee and Operational Metrics - The total employee costs for 2024 amounted to RMB 133,971,000, an increase of 19.8% compared to RMB 111,753,000 in 2023[1]. - As of December 31, 2024, the company had approximately 1,415 employees, an increase from 1,244 employees as of December 31, 2023[117]. - The company plans to implement a share-based payment incentive plan for employees, with a total of 6,332,340 shares to be granted[96]. Audit and Compliance - The audit committee has reviewed the consolidated financial information for the year ending December 31, 2024, discussing risk management and internal controls[128]. - The independent auditor has confirmed that the performance figures for the year ending December 31, 2024, align with the consolidated financial statements[129].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 PW MEDTECH GROUP LIMITED 普 華 和 順 集 團 公 司 （ 於開曼群島註冊成立的有限公司） （股份代號：1358） 海外監管公告 附屬公司業績 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 本公司為一間於二零一一年五月十三日根據開曼群島法律註冊成立的獲豁免有限公司。本 公司的主要業務活動為投資控股。本集團主要於中華人民共和國（「中國」）從事研究及開發 （「研發」）、製造及銷售(i)高端輸液器、靜脈留置針產品、胰島素針等，(ii)血液淨化醫療器 械，及(iii)動物源性再生醫用生物材料及人體組織修復替代產品。 四川睿健醫療為一間於二零一三年八月六日在中國成立的股份有限公司，其股份在全國中 小企業股份轉讓系統掛牌交易（ 股份代碼：874652 ）。四川睿健醫療為一間醫療器械公司， 主要從事研發、製造及銷售血液淨化醫療器械。 單位：人民幣萬元 | | 二零二 ...